IBA – Transparency Notification

Louvain-la-Neuve, Belgium, February 18, 2020, 17.30Summary of the notificationIBA (Ion Beam Applications SA), the world’s leading provider of proton therapy solutions for the treatment of cancer, announces that it has to issue a transparency notification, in accordance with Article 14, al. 1 of the Transparency Law of May 2, 2007 on disclosure of major holdings, further to the notification received on February 17, 2020.In its notification, Norges Bank has notified, that following an acquisition of IBA shares with voting rights and a disposal of equivalent financial instruments, its total holding in IBA SA remains the same as in its previous notification but its holding in voting rights has crossed upwards the 3% threshold on February 14, 2020.In details, on February 14, 2020, Norges Bank owned (A) 961.258 IBA shares with voting rights (versus 707.489 shares in its previous notification), representing 3.19 % of the total number of shares issued by IBA (30 133 920) (versus 2.35% in its previous notification), as well as (B) 447.811 equivalent financial instruments (versus 701.580 in its previous notification) representing 1.49% of the total number of shares issued by IBA (30 133 920) (versus 2.33% in its previous notification).Content of the notificationReason for the notification: Acquisition or disposal of voting securities or voting rightsPersons subject to the notification requirement: Norges BankDate on which the threshold is crossed: 14/02/2020Threshold crossed (in %): 3%Denominator: 30 133 920Notified details: (extract of the received notification form)           Full chain of controlled undertakings through which the holding is effectively heldNorges Bank is the central bank of Norway. As part of its central bank activities, Norges Bank manages Norway’s foreign exchange reserves and is responsible for management of the Norwegian Government Pension Fund Global (GPFG). The formal responsibility for management of the GPFG is placed with the Ministry of Finance, but is delegated to Norges Bank. All investments are executed by Norges Bank acting as principal and all holdings are registered in the name of Norges Bank.For further information, please contact:IBAElodie Jaumain
Paralegal
+32 10 203 180legal@iba-group.comAbout IBAIBA (Ion Beam Applications S.A.) is a global medical technology company focused on bringing integrated and innovative solutions for the diagnosis and treatment of cancer. The company is the worldwide technology leader in the field of proton therapy, considered to be the most advanced form of radiation therapy available today. IBA’s proton therapy solutions are flexible and adaptable, allowing customers to choose from universal full-scale proton therapy centers as well as compact, single room solutions. In addition, IBA also has a radiation dosimetry business and develops particle accelerators for the medical world and industry. Headquartered in Belgium and employing about 1,500 people worldwide, IBA has installed systems across the world.IBA is listed on the pan-European stock exchange NYSE EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB). More information can be found at: www.iba-worldwide.comAttachment200218transparencyNorgesEN(au-dessus3%)